Search research articles
Contact Us
Filters
Showing results (101-110 of 119) with videos related to
Page
of 12
Sort By:
European Heart Journal
|
March 5, 2024
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
Nabil V Sayour, Ágnes M Paál, Pietro Ameri, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
February 27, 2021
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Emma Forton Magavern, Juan Carlos Kaski, Richard M Turner, et al.
The Lancet. Rheumatology
|
November 22, 2025
Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries
Eleana Bolla, Anne Grete Semb, Michelle Petri, et al.
BMC Musculoskeletal Disorders
|
July 6, 2013
Hand, hip and knee osteoarthritis in a Norwegian population-based study--the MUST protocol
Nina Østerås, May Arna Risberg, Tore K Kvien, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 9, 2019
Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases
Gianluigi Savarese, Martin F Reiner, Alicia Uijl, et al.
Giornale Italiano Di Cardiologia (2006)
|
December 24, 2025
[2025 ESC Guidelines for the management of myocarditis and pericarditis]
Jeanette Schulz-Menger, Valentino Collini, Jan Gröschel, et al.
European Journal of Heart Failure
|
October 22, 2025
European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action
Mark Luedde, Stefan Agewall, Giuseppe Ambrosio, et al.
European Heart Journal
|
August 29, 2025
2025 ESC Guidelines for the management of myocarditis and pericarditis
Jeanette Schulz-Menger, Valentino Collini, Jan Gröschel, et al.
Rheumatology International
|
April 18, 2025
Methotrexate associates with ischemic cardiovascular risk reduction in males but not females: a transatlantic cardiovascular consortium for people with rheumatoid arthritis observational study
George A Karpouzas, Sarah R Ormseth, Piet Van Riel, et al.
RMD Open
|
July 23, 2024
Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis
George Athanasios Karpouzas, Sarah R Ormseth, Piet Leonardus Cornelis Maria van Riel, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 119) with videos related to
Sort By:
Page
of 12
European Heart Journal
|
March 5, 2024
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
Nabil V Sayour, Ágnes M Paál, Pietro Ameri, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
February 27, 2021
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Emma Forton Magavern, Juan Carlos Kaski, Richard M Turner, et al.
The Lancet. Rheumatology
|
November 22, 2025
Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries
Eleana Bolla, Anne Grete Semb, Michelle Petri, et al.
BMC Musculoskeletal Disorders
|
July 6, 2013
Hand, hip and knee osteoarthritis in a Norwegian population-based study--the MUST protocol
Nina Østerås, May Arna Risberg, Tore K Kvien, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 9, 2019
Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases
Gianluigi Savarese, Martin F Reiner, Alicia Uijl, et al.
Giornale Italiano Di Cardiologia (2006)
|
December 24, 2025
[2025 ESC Guidelines for the management of myocarditis and pericarditis]
Jeanette Schulz-Menger, Valentino Collini, Jan Gröschel, et al.
European Journal of Heart Failure
|
October 22, 2025
European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action
Mark Luedde, Stefan Agewall, Giuseppe Ambrosio, et al.
European Heart Journal
|
August 29, 2025
2025 ESC Guidelines for the management of myocarditis and pericarditis
Jeanette Schulz-Menger, Valentino Collini, Jan Gröschel, et al.
Rheumatology International
|
April 18, 2025
Methotrexate associates with ischemic cardiovascular risk reduction in males but not females: a transatlantic cardiovascular consortium for people with rheumatoid arthritis observational study
George A Karpouzas, Sarah R Ormseth, Piet Van Riel, et al.
RMD Open
|
July 23, 2024
Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis
George Athanasios Karpouzas, Sarah R Ormseth, Piet Leonardus Cornelis Maria van Riel, et al.
Page
of 12